The National Cancer Institute (NCI) has purchased Caliper Life Sciences' Quantum FX, a standalone microCT system for pre-clinical imaging, to study spontaneous tumour models in lung cancer.
The selection of the Quantum FX by the NCI validates the need for a low-radiation dose microCT imaging system.
Unlike traditional microCT systems that use higher dose radiation, the Quantum FX allows longitudinal studies and provides more accurate, detailed and clinically relevant data, throughout the drug discovery and development process.
This approach, which has broad utility in the research space, is critical to fully understand the progression of lung cancer, as well as the efficacy of chemotherapeutic agents.
The images captured on the Quantum FX can be co-registered with other imaging modalities, providing a more complete picture of disease.
The Quantum FX is a critical tool to support the preclinical development of better targeted and safer therapies for the millions of patients suffering from lung cancer.